Curis Stock News

During the last session, Curis Inc. (NASDAQ:CRIS)s traded shares were 3.56 million, with the beta value of the company hitting 2.84. At the end of the trading day, the stocks price was $4.79, reflecting an intraday gain of 7.16% or $0.32. The 52-week high for the CRIS share is $17.40, that puts it down -263.26 How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs? Read More »

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. […]

Zacks Investment Research upgraded shares of Curis (NASDAQ:CRIS) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $5.00 price objective on the biotechnology companys stock. According to Zacks, Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, []

Curis (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Monday, Zacks.com reports. The firm presently has a $5.00 price objective on the biotechnology companys stock. Zacks Investment Researchs target price would indicate a potential upside of 2.25% from the companys [] The post Curis (NASDAQ:CRIS) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .

Colony Family Offices LLC trimmed its position in shares of Curis, Inc. (NASDAQ:CRIS) by 28.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,387 shares of the biotechnology companys stock after selling 8,000 shares during the quarter. Curis accounts for approximately 0.1% of []

Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and []

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Curis Inc. (NASDAQ:CRIS) has a beta value of 2.78 and has seen 1.59 million shares traded in the last trading session. The company, currently valued at $478.07M, closed the last trade at $5.10 per share which meant it gained $0.02 on the day or 0.39% during that session. The CRIS stock price is -241.18% off Why Do Investors Buy Stock In Curis Inc. (CRIS)? Read More »

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Str

Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Str